ACE-083 increased muscle volume in FSHD without improving strength

What is ACE-083 designed to do?

ACE-083 is a locally injected follistatin fusion protein, delivered directly into a single target muscle rather than systemically. The randomized Phase 2 trial describes ACE-083 as a "muscle-promoting agent" built on the general logic of follistatin biology: neutralizing myostatin and activin, growth factors that normally cap how much a muscle fiber can enlarge ^[4].

That mechanism is design rationale, not separately confirmed pharmacokinetics. What the trial confirms is the architecture built around it: intramuscular injection meant to grow one targeted muscle, the biceps brachii or the tibialis anterior, while avoiding the systemic exposure that has limited other myostatin-pathway drugs.

How was the ACE-083 FSHD trial designed?

The ACE-083 trial was a two-part Phase 2 study in adults with FSHD1 or FSHD2 ^[4]. Part 1 was open-label dose escalation in 37 participants, establishing safety, not efficacy.

Part 2 was the controlled portion. It randomized 58 participants to 240 mg per muscle or placebo, injected bilaterally every three weeks into the biceps brachii or tibialis anterior. Part 2 ran double-blind for six months, followed by six months open-label ^[4].

Did ACE-083 build real muscle in FSHD?

ACE-083 built real muscle on MRI: total muscle volume, the primary endpoint, rose 16.4% in the biceps brachii and 9.5% in the tibialis anterior versus placebo ^[4].

Those figures are least-squares mean differences versus placebo: 16.4% in the biceps group (90% CI 9.8-23.0, p<.0001) and 9.5% in the tibialis anterior group (90% CI 3.2-15.9, p=.01) ^[4]. On imaging, ACE-083 did what the mechanism predicts.

Contractile muscle volume, the imaging estimate of muscle tissue rather than intramuscular fat, also increased significantly, and fat fraction decreased in both groups ^[4]. By every imaging measure used, the growth was real muscle, not swelling.

Did ACE-083 improve strength or function?

No. ACE-083 produced no meaningful treatment effect on strength, patient-reported outcomes, or the muscle-matched functional tests ^[4].

The functional tests were six-minute walk distance, 10-meter walk/run, and four-stair climb for the leg group, and a validated upper-limb performance score for the arm group ^[4]. A drug that reliably added 9 to 16 percent more muscle volume, confirmed as contractile tissue, left walking speed, stair climbing, and arm function essentially where placebo left them.

Why did ACE-083's added muscle not make FSHD patients stronger?

FSHD muscle mixes surviving fibers with fibrofatty replacement tissue, and ACE-083's local blockade grows healthy and dysfunctional fibers alike, adding volume without necessarily adding usable force.

Some surviving fibers in FSHD muscle already have compromised innervation or excitation-contraction coupling. Local myostatin and activin blockade has no way to distinguish healthy contractile fiber from those already-dysfunctional fibers.

Does added muscle usually bring added strength?

In healthy or minimally impaired muscle, tissue added through resistance training generally does track with strength. Large training literatures in healthy adult men show consistent muscle mass gains from resistance training ^[1], and older adults with osteoarthritis gain both lean mass and cross-sectional area from strength training versus non-exercise controls ^[2].

Studies that isolate which fibers hypertrophy, such as selective hamstring growth from Nordic curls versus stiff-leg deadlifts, find strength gains accompanying that selective growth in untrained, non-pathological muscle ^[5]. Comparisons across different resistance-training protocols in healthy lifters find hypertrophy and strength moving together regardless of method ^[6]. ACE-083's dissociation is notable because it breaks that usual coupling, in muscle that was already structurally compromised before treatment.

The closer precedent for a size marker moving without functional payoff sits outside muscle disease, in sports nutrition. A meta-analysis of HMB supplementation in resistance-trained young adults found a significant increase in total body mass but no significant gain in fat-free mass or strength ^[3]. The tissue and mechanism differ, but the lesson is the same: a mass or volume number moving on its own is not evidence that the tissue behind it is functionally relevant. The same gap between mass and strength appears in growth hormone research.

Is MRI muscle volume a valid surrogate for strength in muscle disease?

MRI-measured muscle volume, however precisely quantified, is not automatically a valid surrogate for strength or function in dystrophic muscle, and the ACE-083 trial is one of the cleanest human demonstrations of that ^[4].

The FSHD trial establishes directly that, in a placebo-controlled human trial, follistatin-driven local muscle growth and functional improvement were measurably different things. Reporting the volume figure alone misrepresents what happened ^[4].

What happened to the ACE-083 program?

Public reporting indicates the developer discontinued the ACE-083 program. The decision is unverified, and the FSHD trial report does not document it.

A parallel program reportedly tested ACE-083 in Charcot-Marie-Tooth disease and showed a similar volume-without-function pattern. Its numbers are unconfirmed, and so is the reasoning behind the discontinuation.

What is still unknown about ACE-083?

Three questions remain open after the FSHD trial:

• Other regimens. Whether longer treatment, a different injected muscle, or combination with a training stimulus could have produced a functional signal is untested.
• Healthy muscle. Whether the same split applies to non-dystrophic, healthy muscle is unproven. The closest healthy-muscle evidence shows hypertrophy and strength usually moving together ^[1]⁠^[2]⁠^[5]⁠^[6], which is why the ACE-083 result stands out rather than reflecting ordinary muscle physiology.
• Other molecules. Whether the size-function split generalizes to other myostatin- or activin-pathway molecules, including systemically delivered ones, is not established.